NASDAQ · ITCI
Healthcare · Drug Manufacturers - Specialty & Generic
$131.87
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 10:21 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ITCI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ITCI.
ITCI research
Company profile and research snapshot.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2025 | Cantor Fitzgerald | Neutral | — |
| Feb 24, 2025 | Mizuho | Neutral | — |
| Feb 21, 2025 | Needham | Hold | — |
| Jan 31, 2025 | Canaccord Genuity | Hold | — |
| Jan 22, 2025 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 21, 2025
Intra-Cellular Therapies' CAPLYTA, an antipsychotic drug, is gaining traction in the market for treating schizophrenia and bipolar depression, with its differentiated safety profile and broad efficacy.
GlobeNewswire Inc. · Feb 21, 2025
Intra-Cellular Therapies reported strong financial results for Q4 2024, with CAPLYTA net product sales growing 51% year-over-year. The company also announced the FDA's acceptance of a supplemental New Drug Application for CAPLYTA as an adjunctive treatment for major depressive disorder.
GlobeNewswire Inc. · Feb 4, 2025
Halper Sadeh LLC is investigating the proposed sales of Logility Supply Chain Solutions, Enfusion, Intra-Cellular Therapies, and Shutterstock to determine if the transactions are fair to shareholders.
The Motley Fool · Feb 1, 2025
Johnson & Johnson announced plans to acquire Intra-Cellular Therapies for $14.6 billion, which could bolster its pipeline and strengthen its neurological business. However, the acquisition is unlikely to turn Johnson & Johnson into a high-growth stock, as its growth rate is expected to remain in the single digits.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ITCI.
No results
No recent SID articles mention ITCI.
